Intracameral moxifloxacin: A safe option for endophthalmitis prophylaxis?;Moxifloxacin intrakameral: Eine sichere Option zur Endophthalmitisprophylaxe?

Ophthalmologe

Volumn 107, Issue 8, 2010, Pages 720-727

  Kernt, M ^a   Hirneiss, C ^a   Neubauer, A S ^a   Liegl, R G ^a   Eibl, K H ^a   Wolf, A ^a   de Kaspar, H ^a,b   Ulbig, M W ^a   Kampik, A ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotics; Endophthalmitis; Fluoroquinolones; Intracameral drug delivery; Moxifloxacin

Indexed keywords

ANTIINFECTIVE AGENT; AUTACOID; HETEROCYCLIC COMPOUND; LIPOPOLYSACCHARIDE; MOXIFLOXACIN; QUINOLINE DERIVATIVE;

ANTERIOR EYE CHAMBER; ARTICLE; CELL COUNT; CELL CULTURE; CELL SURVIVAL; CORNEA EPITHELIUM; DOSE RESPONSE; DRUG EFFECT; ENDOPHTHALMITIS; ENDOTHELIUM CELL; HUMAN; IMMUNOLOGY; IN VITRO STUDY; LENS; METABOLISM; OXIDATIVE STRESS; PIGMENT EPITHELIUM; TRABECULAR MESHWORK;

ANTERIOR CHAMBER; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; CELL COUNT; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOPHTHALMITIS; ENDOTHELIAL CELLS; EPITHELIUM, CORNEAL; HUMANS; INFLAMMATION MEDIATORS; LENS, CRYSTALLINE; LIPOPOLYSACCHARIDES; OXIDATIVE STRESS; PIGMENT EPITHELIUM OF EYE; QUINOLINES; TRABECULAR MESHWORK;

EID: 77955813850     PISSN: 0941293X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00347-009-2027-9     Document Type: Article

References (44)

1. (n a) (2007) Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors. J Cataract Refract Surg 33: 978-988.
2. (n a) (1995) Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Endophthalmitis Vitrectomy Study Group. Arch Ophthalmol 113: 1479-1496.
3. Aaberg TM Jr, Flynn HW Jr, Murray TG (1994) Intraocular ceftazidime as an alternative to the aminoglycosides in the treatment of endophthalmitis. Arch Ophthalmol 112: 18-19.
4. Aaberg TM Jr, Flynn HW Jr, Schiffman J, Newton J (1998) Nosocomial acute-onset postoperative endophthalmitis survey. A 10-year review of incidence and outcomes. Ophthalmology 105: 1004-1010.
5. Axer-Siegel R, Stiebel-Kalish H, Rosenblatt I et al (1999) Cystoid macular edema after cataract surgery with intraocular vancomycin. Ophthalmology 106: 1660-1664.
6. Aydin E, Kazi AA, Peyman GA, Esfahani MR (2006) Intravitreal toxicity of moxifloxacin. Retina 26: 187-190.
7. Benz MS, Scott IU, Flynn HW Jr et al (2004) Endophthalmitis isolates and antibiotic sensitivities: a 6-year review of culture-proven cases. Am J Ophthalmol 137: 38-42.
8. Blondeau JM (2004) Fluoroquinolones: mechanism of action, classification, and development of resistance. Surv Ophthalmol 49(Suppl 2): S73-S78.
9. Callegan MC, Ramirez R, Kane ST et al (2003) Antibacterial activity of the fourth-generation fluoroquinolones gatifloxacin and moxifloxacin against ocular pathogens. Adv Ther 20: 246-252.
10. Congdon N, Vingerling JR, Klein BE et al (2004) Prevalence of cataract and pseudophakia/aphakia among adults in the United States. Arch Ophthalmol 122: 487-494.
11. Deramo VA, Lai JC, Fastenberg DM, Udell IJ (2006) Acute endophthalmitis in eyes treated prophylactically with gatifloxacin and moxifloxacin. Am J Ophthalmol 142: 721-725.
12. Ermis SS, Cetinkaya Z, Kiyici H et al (2007) Effects of intravitreal moxifloxacin and dexamethasone in experimental Staphylococcus aureus endophthalmitis. Curr Eye Res 32: 337-344.
13. Ermis SS, Cetinkaya Z, Kiyici H, Ozturk F (2005) Treatment of Staphylococcus epidermidis endophthalmitis with intravitreal moxifloxacin in a rabbit model. Tohoku J Exp Med 205: 223-229.
14. Espiritu CR, Caparas VL, Bolinao JG (2007) Safety of prophylactic intracameral moxifloxacin 0. 5% ophthalmic solution in cataract surgery patients. J Cataract Refract Surg 33: 63-68.
15. Feys J, Emond JP, Salvanet-Bouccara A, Dublanchet A (1994) Interleukin-6 and other cytokines in the aqueous humor in uveitis and endophthalmitis. J Fr Ophtalmol 17: 634-639.
16. Gao H, Pennesi ME, Qiao X et al (2006) Intravitreal moxifloxacin: retinal safety study with electroretinography and histopathology in animal models. Invest Ophthalmol Vis Sci 47: 1606-1611.
17. Giese MJ, Sumner HL, Berliner JA, Mondino BJ (1998) Cytokine expression in a rat model of Staphylococcus aureus endophthalmitis. Invest Ophthalmol Vis Sci 39: 2785-2790.
18. Hariprasad SM, Blinder KJ, Shah GK et al (2005) Penetration pharmacokinetics of topically administered 0. 5% moxifloxacin ophthalmic solution in human aqueous and vitreous. Arch Ophthalmol 123: 39-44.
19. Javitt JC, Street DA, Tielsch JM et al (1994) National outcomes of cataract extraction. Retinal detachment and endophthalmitis after outpatient cataract surgery. Cataract Patient Outcomes Research Team. Ophthalmology 101: 100-105; discussion 106.
20. Kattan HM, Flynn HW Jr, Pflugfelder SC et al (1991) Nosocomial endophthalmitis survey. Current incidence of infection after intraocular surgery. Ophthalmology 98: 227-238.
21. Kernt M, Neubauer AS, HM DEK, Kampik A (2008) INTRAVITREAL VORICONAZOLE: In Vitro Safety-Profile for Fungal Endophthalmitis. Retina 29: 362-370.
22. Kernt M, Neubauer AS, Liegl RG et al (2009) Intracameral Moxifloxacin: In Vitro Safety on Human Ocular Cells. Cornea.
23. Kernt M, Neubauer AS, Ulbig MW et al (2008) In vitro safety of intravitreal moxifloxacin for endophthalmitis treatment. J Cataract Refract Surg 34: 480-488.
24. Kernt M, Welge-Lussen U, Yu A et al (2007) Bevacizumab is not toxic to human anterior- and posterior-segment cultured cells. Ophthalmologe 104: 965-971.
25. Kim SY, Park YH, Lee YC (2008) Comparison of the effect of intracameral moxifloxacin, levofloxacin and cefazolin on rabbit corneal endothelial cells. Clin Experiment Ophthalmol 36: 367-370.
26. Koss MJ, Eder M, Blumenkranz MS et al (2007) The effectiveness of the new fluoroquinolones against the normal bacterial flora of the conjunctiva. Ophthalmologe 104: 21-27.
27. Kowalski RP, Romanowski EG, Mah FS et al (2005) Intracameral Vigamox (moxifloxacin 0. 5%) is non-toxic and effective in preventing endophthalmitis in a rabbit model. Am J Ophthalmol 140: 497-504.
28. Kunimoto DY, Das T, Sharma S et al (1999) Microbiologic spectrum and susceptibility of isolates: part I. Postoperative endophthalmitis. Endophthalmitis Research Group. Am J Ophthalmol 128: 240-242.
29. Kunimoto DY, Sharma S, Garg P, Rao GN (1999) In vitro susceptibility of bacterial keratitis pathogens to ciprofloxacin. Emerging resistance. Ophthalmology 106: 80-85.
30. Mamalis N, Edelhauser HF, Dawson DG et al (2006) Toxic anterior segment syndrome. J Cataract Refract Surg 32: 324-333.
31. Masket S (1998) Preventing, diagnosing, and treating endophthalmitis. J Cataract Refract Surg 24: 725-726.
32. Mather R, Karenchak LM, Romanowski EG, Kowalski RP (2002) Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol 133: 463-466.
33. McCulley JP, Caudle D, Aronowicz JD, Shine WE (2006) Fourth-generation fluoroquinolone penetration into the aqueous humor in humans. Ophthalmology 113: 955-959.
34. Metzler K, Hansen GM, Hedlin P et al (2004) Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus. Int J Antimicrob Agents 24: 161-167.
35. Miller JJ, Scott IU, Flynn HW Jr et al (2005) Acute-onset endophthalmitis after cataract surgery (2000-2004): incidence, clinical settings, and visual acuity outcomes after treatment. Am J Ophthalmol 139: 983-987.
36. Mo JS, Streilein JW (2001) Immune privilege persists in eyes with extreme inflammation induced by intravitreal LPS. Eur J Immunol 31: 3806-3815.
37. Rossi C, Sternon J (2001) Flouroquinolones of the third and fourth generations. J Pharm Belg 56: 137-148.
38. Satofuka S, Ichihara A, Nagai N et al (2006) Suppression of ocular inflammation in endotoxin-induced uveitis by inhibiting nonproteolytic activation of prorenin. Invest Ophthalmol Vis Sci 47: 2686-2692.
39. Schentag JJ (2002) Pharmacokinetic and pharmacodynamic predictors of antimicrobial efficacy: moxifloxacin and Streptococcus pneumoniae. J Chemother 14(Suppl 2): 13-21.
40. Smith A, Pennefather PM, Kaye SB, Hart CA (2001) Fluoroquinolones: place in ocular therapy. Drugs 61: 747-761.
41. Thomas J, Kanangat S, Rouse BT (1998) Herpes simplex virus replication-induced expression of chemokines and proinflammatory cytokines in the eye: implications in herpetic stromal keratitis. J Interferon Cytokine Res 18: 681-690.
42. Villada JR, Vicente U, Javaloy J, Alio JL (2005) Severe anaphylactic reaction after intracameral antibiotic administration during cataract surgery. J Cataract Refract Surg 31: 620-621.
43. West ES, Behrens A, McDonnell PJ et al (2005) The incidence of endophthalmitis after cataract surgery among the U. S. Medicare population increased between 1994 and 2001. Ophthalmology 112: 1388-1394.
44. Yoeruek E, Spitzer MS, Saygili O et al (2008) Comparison of in vitro safety profiles of vancomycin and cefuroxime on human corneal endothelial cells for intracameral use. J Cataract Refract Surg 34: 2139-2145.